Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Core Insights - Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study, indicating progress in their research efforts [1] - The company highlighted new findings related to the VARIPULSE Platform, suggesting advancements in technology and potential applications in the healthcare sector [1] Group 1 - The OMNY-AF study provides critical data that may influence future clinical practices and treatment options [1] - The VARIPULSE Platform's new findings could enhance the company's product offerings and competitive positioning in the market [1]